Marotta Asset Management reduced its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN – Free Report) by 21.8% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 12,891 shares of the company’s stock after selling 3,603 shares during the period. Marotta Asset Management’s holdings in Haleon were worth $134,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bartlett & CO. Wealth Management LLC grew its position in Haleon by 135.9% during the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 2,588 shares of the company’s stock worth $27,000 after purchasing an additional 1,491 shares during the period. Banque Transatlantique SA acquired a new stake in shares of Haleon during the 1st quarter valued at about $27,000. Opal Wealth Advisors LLC acquired a new stake in shares of Haleon during the 1st quarter valued at about $29,000. Ransom Advisory Ltd acquired a new stake in shares of Haleon during the 1st quarter valued at about $31,000. Finally, Deutsche Bank AG grew its position in shares of Haleon by 267.8% during the 1st quarter. Deutsche Bank AG now owns 3,126 shares of the company’s stock valued at $32,000 after acquiring an additional 2,276 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.
Haleon Trading Down 0.7%
HLN stock opened at $9.81 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.48. Haleon PLC Sponsored ADR has a 12-month low of $8.86 and a 12-month high of $11.42. The stock has a market cap of $43.91 billion, a price-to-earnings ratio of 25.14, a PEG ratio of 2.91 and a beta of 0.24. The business’s 50-day moving average is $9.73 and its 200 day moving average is $10.20.
Haleon Increases Dividend
Wall Street Analyst Weigh In
HLN has been the topic of a number of analyst reports. The Goldman Sachs Group upgraded Haleon from a “neutral” rating to a “buy” rating in a research report on Wednesday. BNP Paribas upgraded Haleon to a “strong-buy” rating in a research report on Tuesday, May 27th. BNP Paribas Exane upgraded Haleon from a “neutral” rating to an “outperform” rating and set a $13.40 target price on the stock in a research report on Tuesday, May 27th. Finally, Wall Street Zen cut Haleon from a “buy” rating to a “hold” rating in a research report on Saturday, July 12th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $12.33.
View Our Latest Stock Report on Haleon
Haleon Profile
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Featured Articles
- Five stocks we like better than Haleon
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Tesla’s U.S. Market Is At An 8-Year Low… How Bad Could It Get?
- ESG Stocks, What Investors Should Know
- Congress: The Biggest Trades Impacting Markets Today
- What Are Dividend Challengers?
- 3 Companies Boosting Buybacks While Others Pull Back
Want to see what other hedge funds are holding HLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haleon PLC Sponsored ADR (NYSE:HLN – Free Report).
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.